Visiox

What Visiox does

Visiox is a privately held biopharmaceutical company founded in 2022 and headquartered in Tarrytown, New York. The company develops and commercializes treatments for ophthalmic conditions, with a primary focus on glaucoma and post-surgical ocular inflammation and pain. Its lead asset is OMLONTI®, a glaucoma therapy distinguished by a dual mechanism of action, positioned within the U.S. specialty ophthalmology market.

Visiox operated with a lean team of 1–10 employees and was capitalized with a $7 million seed round raised in August 2022. In August 2024, Visiox merged with Ocuvex Therapeutics, forming a combined ophthalmology-focused entity intended to broaden the therapeutic pipeline beyond glaucoma into post-surgical inflammation and pain. Leadership disclosed includes Cynthia Matossian as Chief Medical Officer and Sanjay Malieckal as VP of Sales & Marketing.

The business model centers on selling an approved pharmaceutical product (OMLONTI®) through healthcare provider channels — primarily ophthalmologists and optometrists — with end users being patients with glaucoma or post-surgical ophthalmic needs. No pricing, payor mix, or revenue mechanics were disclosed in the available input. The combined entity now operates under the Ocuvex Therapeutics brand (ocuvextherapeutics.com), reflecting the post-merger commercial identity.

Name

Visiox

Legal name

Ocuvex Therapeutics Inc.

Website

https://visioxpharma.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Visiox is a Tarrytown-based biopharmaceutical company founded in 2022 that develops ophthalmic treatments, including the dual-mechanism glaucoma therapy OMLONTI®. In August 2024 it merged with Ocuvex Therapeutics to broaden its ophthalmology pipeline.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Ophthalmology Pharmaceuticals (HLAIAAAL)

akta.pro secondary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

Keywords

• Ophthalmic pharmaceuticals
• Glaucoma treatment
• Specialty branded drugs
• Eye care therapeutics
• Post-surgical ophthalmology

Headquarters

HQ city

Tarrytown

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations

Revenue model

1. Pharmaceutical product sales: Revenue generated from the sale of specialty ophthalmic pharmaceuticals including OMLONTI and pipeline products targeting glaucoma and post-surgical inflammation markets.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Visiox (now operating as Ocuvex Therapeutics Inc.) develops and commercializes specialty branded pharmaceuticals for ophthalmology. Its lead product, OMLONTI®, is a prescription ophthalmic medication employing a dual mechanism to lower intraocular pressure in glaucoma patients. The company also maintains a development pipeline targeting post-surgical ocular inflammation and pain, with the goal of addressing unmet needs in eye care therapeutics.

Product overview

Visiox (now merged with Ocuvex Therapeutics) is a pharmaceutical company with global reach focused on developing specialty innovative branded pharmaceuticals and healthcare products in ophthalmology. The company offers OMLONTI® for glaucoma treatment and maintains a pipeline focused on glaucoma and post-surgical inflammation and pain. The merger combined Visiox's products with Ocuvex's resources to accelerate commercialization of eye care therapeutics.

Differentiator

Problem solved

Functional benefit

Brands

• OMLONTI®: A glaucoma treatment offering dual mechanism to lower ocular pressure.

Products and services

• OMLONTI® A prescription ophthalmic medication offering a dual mechanism to lower ocular pressure for glaucoma patients. Recently launched by Ocuvex Therapeutics and targeted at ophthalmologists and healthcare professionals treating patients with glaucoma, a group of eye conditions that damage the optic nerve.
• Post-surgical ophthalmic inflammation and pain pipeline A development pipeline focused on therapies for managing post-surgical ocular inflammation and pain, targeting patients recovering from eye surgery. Aimed at ophthalmologists and eye-care providers seeking improved recovery outcomes, reduced complications, and enhanced patient satisfaction.

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Ocuvex Therapeutics, Inc.coreStrategic or Co-development Partner · 19 August 2024Visiox Pharmaceuticals, Inc. announced a transformative merger with Ocuvex Therapeutics, Inc. in August 2024 to strengthen its position in the ophthalmic market. The merger aimed to accelerate commercialization of products, resulting in a new entity operating under the Ocuvex name, focusing on eye care therapeutics with a promising pipeline.

Scale indicators2 records

Recent moves4 records

Expansion highlights3 records

Direct peers

• Aerie Pharmaceuticals: A specialty ophthalmic pharmaceutical company focused on glaucoma and other eye diseases. Directly comparable to Visiox/Ocuvex as a focused, branded ophthalmology pharma with FDA-approved glaucoma products.
• Ocular Therapeutix: Specialty biopharmaceutical company developing therapies for ophthalmic conditions including glaucoma and post-surgical care. Comparable in size, therapeutic focus, and specialty branded-pharma model targeting the same physician channels.
• EyePoint Pharmaceuticals: Specialty ophthalmic pharma developing treatments for retinal diseases and ocular conditions. Comparable as a small-cap, branded ophthalmology company with a recently commercialized product portfolio.

Emerging players

• Tarsus Pharmaceuticals: Late-stage specialty biopharma with a recently launched ophthalmic product (Xdemvy for Demodex blepharitis). Comparable as a small commercial-stage ophthalmology innovator targeting eye care specialists.
• Nicox SA: European ophthalmology company developing therapeutics for glaucoma and other eye diseases. Comparable as a focused, branded ophthalmic pharma player targeting IOP reduction and ocular surface disease.
• Kala Bio: Clinical-stage biopharmaceutical company developing novel therapies for ocular surface diseases. Comparable as a small, specialized ophthalmology biotech with branded-product ambitions in eye care.

Broad incumbents

• Bausch + Lomb: Major global eye-health company with a broad ophthalmic pharmaceutical and surgical product portfolio including branded glaucoma therapies. Comparable as a competitor and potential partner/distributor serving the same physician channels.
• Alcon: Global leader in eye care with extensive pharmaceutical, surgical, and vision-care franchises including major glaucoma brands. Comparable as the dominant incumbent in ophthalmic pharmaceuticals that Visiox/Ocuvex competes against.
• Allergan (AbbVie): Major ophthalmic pharmaceutical franchise under AbbVie with leading branded glaucoma products. Comparable as the dominant incumbent in branded IOP-lowering therapy that sets the competitive benchmark.

Regional players

• Santen Pharmaceutical: Japan-based global ophthalmology company with a strong portfolio in glaucoma and ocular surface disease. Comparable as a specialty ophthalmic pharma competitor with similar therapeutic focus, though primarily Asia-based.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Visiox